FDA-Approved Drugs That Disappointed in 2013: Ariad’s Iclusig
Insights - First up, Ariad Pharmaceuticals’ (ARIA) Iclusig. ARIA has regained almost 50%, or $932 million, in lost market value since U.S. regulators announced the resumption in marketing … Continue Reading
Read now